We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+75.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$495M
AUM Growth
+$118M
Cap. Flow
-$4.08M
Cap. Flow %
-0.82%
Top 10 Hldgs %
52.26%
Holding
60
New
16
Increased
13
Reduced
8
Closed
12
Avg Time Held Equity + Options
4.4 quarters
Top 10 Avg Time Held Equity + Options
2.8 quarters
Top 20 Avg Time Held Equity + Options
3.6 quarters
Avg Time Held Equity only
4.4 quarters
Top 10 Avg Time Held Equity only
2.8 quarters
Top 20 Avg Time Held Equity only
3.6 quarters

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$9.48M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.2M
3
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.09M
4
OCUL icon
Ocular Therapeutix
OCUL
+$5.71M
5
CYTK icon
Cytokinetics
CYTK
+$5.68M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$36.8M
2
APTO
Aptose Biosciences, Inc.
APTO
+$6.39M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.83M
4
KALA icon
KALA BIO
KALA
+$4.76M
5
ZYME icon
Zymeworks
ZYME
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TARA icon
1
Protara Therapeutics
TARA
$160M
$64.8M 13.08%
2,208,472
– –
2019 Q3
3 quarters
OCUL icon
2
Ocular Therapeutix
OCUL
$1.66B
$49.8M 10.07%
5,984,200
+861,700
+17% +$5.71M
2019 Q1
5 quarters
NGNE icon
3
Neurogene
NGNE
$463M
$23.2M 4.69%
70,000
– –
2019 Q3
3 quarters
CCXI icon
4
DELISTED
ChemoCentryx, Inc.
CCXI
$20.8M 4.2%
361,600
– –
2019 Q3
3 quarters
ETON icon
5
Eton Pharmaceutcials
ETON
$1.57B
$19.8M 4.01%
3,640,000
– –
2018 Q4
6 quarters
APTO
6
DELISTED
Aptose Biosciences, Inc.
APTO
$19.8M 3.99%
6,956
-1,982
-22% -$6.39M
2019 Q3
3 quarters
CDXS icon
7
Codexis
CDXS
$152M
$16.1M 3.25%
1,400,000
– –
2014 Q1
25 quarters
STXS icon
8
Stereotaxis
STXS
$109M
$15.7M 3.16%
3,511,500
-350,000
-9% -$1.42M
2019 Q3
3 quarters
EIDX
9
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$14.6M 2.96%
315,550
– –
2018 Q4
6 quarters
HROW icon
10
Harrow
HROW
$1.06B
$14.1M 2.85%
2,710,000
+210,000
+8% +$1.03M
2018 Q3
7 quarters
MYOV
11
DELISTED
Myovant Sciences Ltd.
MYOV
$14.1M 2.84%
682,500
+26,500
+4% +$360K
2020 Q1
1 quarter
MGNX icon
12
MacroGenics
MGNX
$226M
$14M 2.83%
501,000
+78,700
+19% +$1.37M
2019 Q4
2 quarters
CLDX icon
13
Celldex Therapeutics
CLDX
$2.24B
$13.9M 2.81%
+1,071,000
New +$4.75M
2020 Q2
0 quarters
DCPH icon
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.1M 2.64%
222,000
– –
2018 Q1
9 quarters
ATXI icon
15
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$11.1M 2.25%
920
– –
2018 Q4
6 quarters
ODT
16
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$10.6M 2.14%
250,000
-110,000
-31% -$3.56M
2018 Q4
6 quarters
FBIO icon
17
Fortress Biotech
FBIO
$67.7M
$10.3M 2.07%
+255,333
New +$9.48M
2020 Q2
0 quarters
TGTX icon
18
TG Therapeutics
TGTX
$8.24B
$8.89M 1.8%
456,600
-36,400
-7% -$586K
2018 Q1
9 quarters
KNSA icon
19
Kiniksa Pharmaceuticals
KNSA
$6.16B
$8.78M 1.77%
+344,500
New +$7.2M
2020 Q2
0 quarters
AVTX icon
20
Avalo Therapeutics
AVTX
$679M
$8.77M 1.77%
1,171
+406
+53% +$2.95M
2018 Q4
6 quarters
QURE icon
21
uniQure
QURE
$1.47B
$8.55M 1.73%
270,400
+60,400
+29% +$3.57M
2019 Q1
5 quarters
BHVN icon
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.36M 1.69%
+114,350
New +$6.09M
2020 Q2
0 quarters
XOMA icon
23
DELISTED
Xoma
XOMA
$8.21M 1.66%
415,380
+28,380
+7% +$623K
2017 Q1
13 quarters
CRNX icon
24
DELISTED
Crinetics Pharmaceuticals
CRNX
$7.63M 1.54%
435,200
+66,450
+18% +$1.13M
2019 Q1
5 quarters
CYTK icon
25
Cytokinetics
CYTK
$8.66B
$7.14M 1.44%
+303,050
New +$5.68M
2020 Q2
0 quarters
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2020 Portfolio in Review

As of Q2 2020, Opaleye Management held 60 positions worth $495M, up 31% from $377M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opaleye Management's Q2 2020 filing shows 16 new, 13 increased, 8 reduced and 12 closed positions. Its largest new stake was Fortress Biotech: 255,333 shares worth $10.3M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $36.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

  • Opaleye Management's largest Q2 2020 buy was Fortress Biotech: 255,333 shares worth $10.3M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2020, an estimated $5.71M increase.
  • Opaleye Management's biggest Q2 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $6.39M.
  • Opaleye Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $36.8M.
  • Opaleye Management's ten largest holdings make up 52% of its $495M portfolio in Q2 2020.
  • Opaleye Management opened 16 new positions and closed 12 in Q2 2020.
  • Opaleye Management's portfolio value rose 31% quarter-over-quarter to $495M.

Based on Opaleye Management's 13F filing for Q2 2020, filed 14 Aug 2020.